Artemisinin Antimalarial Drugs Market Trends

Artemisinin Antimalarial Drugs Market Trends

• The high prevalence of malaria is a significant driver of the market.
   
• Malaria remains a major global health challenge, particularly in regions with endemic transmission, such as sub-Saharan Africa, Southeast Asia, and parts of South America.
   
• For instance, in 2022, there were an estimated 233 million cases and 608,000 deaths in the WHO African Region, accounting for about 94% of global malaria cases. Asia ranks second to Africa in terms of malaria burden. In 2022, the region reported approximately 16 million cases and 45,600 deaths. Major contributors to the malaria burden in Asia include India, Indonesia, Myanmar, and Pakistan, which collectively account for over 85% of reported cases.
   
• This persistent burden of malaria has led to a continuous demand for effective treatments, with artemisinin-based combination therapies (ACTs) being the cornerstone of malaria treatment due to their high efficacy against Plasmodium falciparum, the most dangerous malaria parasite.
   
• This sustained demand for ACTs fuels market growth, as healthcare systems and organizations strive to reduce malaria incidence and mortality.
   
• Moreover, efforts to combat malaria, including international initiatives and funding for drug development, further bolster the market by ensuring a steady supply of these critical medications.